Last reviewed · How we verify
Anti Xa dosage
At a glance
| Generic name | Anti Xa dosage |
|---|---|
| Sponsor | Les Laboratoires des Médicaments Stériles |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO (PHASE2)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage (NA)
- Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX) (PHASE4)
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
- The Intensive Care Platform Trial (PHASE4)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti Xa dosage CI brief — competitive landscape report
- Anti Xa dosage updates RSS · CI watch RSS
- Les Laboratoires des Médicaments Stériles portfolio CI